TY - JOUR
AR - COR-2020-6-118
TI - Haemolytic Uraemic Syndrome Associated with Docetaxel: A Case Report
AU - Andrew , Short
AU - Anton , Borg
AU - Beshar, Allos
AU - Nawaz , Walji
AU - Verity , Dunn
JO - Clinical Oncology and Research
PY - 2020
DA - Mon 29, Jun 2020
SN - 2613-4942
DO - http://dx.doi.org/10.31487/j.COR.2020.06.18
UR - https://www.sciencerepository.org/haemolytic-uraemic-syndrome-associated-with-docetaxel-a-case-report_COR-2020-6-118 
KW - Adjuvant chemotherapy, breast, docetaxel, drug-related adverse reactions, hemolytic-ureamic syndrome
AB - Haemolytic uraemic syndrome (HUS) has no recognised association with single-agent docetaxel. We
present the first documented case of HUS associated with docetaxel in a patient receiving adjuvant
chemotherapy for early breast cancer. A previously fit 49-year-old presented nineteen days post final cycle
of docetaxel (100 mg/m2
) with general malaise, epistaxis and decreased urine output. Baseline bloods
revealed haemoglobin (53 g/L), urea (45.2 mmol/L), creatinine (1706 µmol/L) and LDH (2140 IU/L).
Tumor lysis syndrome was excluded on further biochemical analysis. Blood film analysis demonstrated
evidence of acanthocytes, anisocytosis and red cell fragments. Septic, viral and autoimmune screens were
negative. There was clear evidence of microangiopathic haemolysis alongside renal dysfunction. She
required dialysis, plasma exchanges and blood transfusions. Renal function and blood counts normalised
within two months post-admission due to prompt and aggressive management. HUS should be considered
in any patient receiving docetaxel who develops simultaneous acute kidney injury and severe anemia.